Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26214
Title: Evaluation of 18F-FMISO PET and 18F-FDG PET Scans in Assessing the Therapeutic Response of Patients With Metastatic Colorectal Cancer Treated With Anti-Angiogenic Therapy.
Austin Authors: Lee, Sze Ting ;Tebbutt, Niall C ;Gan, Hui K ;Liu, Zhanqi;Sachinidis, John;Pathmaraj, Kunthi ;Scott, Andrew M 
Affiliation: Medical Oncology
Surgery (University of Melbourne)
Medicine (University of Melbourne)
Molecular Imaging and Therapy
Olivia Newton-John Cancer Research Institute
School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia
Issue Date: 17-Mar-2021
metadata.dc.date: 2021-03-17
Publication information: Frontiers in Oncology 2021; 11: 606210
Abstract: Tumor hypoxia and angiogenesis are implicated in tumor growth and metastases, and anti-angiogenic therapies have an important role in treating patients with metastatic colorectal cancer. However, the prevalence of hypoxia has not been fully evaluated in colorectal liver metastases, and hypoxic response to anti-angiogenic therapy has not been clearly established. The aims of the study were to evaluate the changes seen on 18F-FMISO and 18F-FDG PET scans in patients treated with anti-angiogenic therapy, and to correlate these measures of hypoxia and metabolism with clinical outcomes, and blood biomarkers of angiogenesis. Patients with metastatic colorectal carcinoma planned for treatment with bevacizumab and chemotherapy received routine staging investigations prior to any treatment, including a FDG PET scan. A FMISO PET scan was performed within 4 weeks of staging tests, with blood specimens collected at that time for serum VEGF and osteopontin measurement. Follow-up FDG and FMISO scans were performed after 1 cycle of treatment. Results were compared to response (RECIST), progression free survival (PFS), and overall survival (OS). A total of 15 patients were recruited into this prospective trial, of which 13 patients were evaluable for assessment of treatment follow-up. Baseline FDG uptake was higher than FMISO uptake, and there was a significant decrease in FDG uptake (SUVmax and TGV) but not FMISO uptake (SUVmax and TNR) after treatment. There was a positive correlation between FDG and FMISO SUVmax on both baseline and post-treatment PET scans. Blood biomarkers of serum VEGF and osteopontin were significantly correlated with the FDG and FMISO PET parameters. This study shows that hypoxia in metastatic colorectal cancer, assessed by FMISO PET, shows minor changes following initial treatment with anti-angiogenic therapy, but is associated with therapeutic response. FDG PET uptake changes (SUVmax, TLG) are also associated with response to anti-angiogenic therapy. These findings demonstrate the interplay between tumor metabolism and hypoxic regulation following anti-angiogenic treatment of metastatic colorectal cancer.
URI: https://ahro.austin.org.au/austinjspui/handle/1/26214
DOI: 10.3389/fonc.2021.606210
PubMed URL: 33816239
ISSN: 2234-943X
Type: Journal Article
Subjects: angiogenesis
bevacizumab
fluoromisonidazole (FMISO) positron emission tomography (PET)
hypoxia
metastatic colorectal carcinoma
response
Appears in Collections:Journal articles

Show full item record

Page view(s)

6
checked on Jun 19, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.